$TEM · Tempus AI, Inc.

Tempus AI filed an 8-K disclosing three agreements with Bristol-Myers Squibb and Pathos AI to expand access to its de-identified multimodal real-world data, analytics software, and agentic AI tools. The deals provide for aggregate cash payments of $192.5 million over approximately five years: $137.5 million from BMS for oncology data and Lens software access, and up to $55 million from Pathos for 500,000 neurology records and an agentic analysis tool. The Pathos component was approved by a special committee of disinterested directors due to related-party overlap.

Stock down 5.83% in the regular session to $63.81 despite the $192.5M deal announcement; extended-hours shows a modest +0.30% bounce to $64.00, suggesting the selloff may be driven by broader market or sector pressure rather than deal reception.

A $192.5M data-licensing commitment from a top-5 global pharma (BMS) validates Tempus's real-world data platform as a revenue-generating asset across multiple therapeutic areas.

This deal deepens Tempus's position as a real-world data provider to big pharma, with BMS joining as a marquee customer for both oncology and (via Pathos) neurology — two of the highest-value therapeutic areas in AI-driven drug development.

The $55M Pathos component is volume-dependent — Tempus only earns the full amount if it delivers all 500,000 records over five years. BMS can terminate the oncology deal early with 12 months' notice, though a substantial termination fee applies.